The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
Publications
Risk of tuberculosis comparison in new users of antitumour necrosis factor-? and with existing disease-modifying antirheumatic drug therapy.
Journal of clinical pharmacy and therapeutics 2018 Apr;43;256-264 — 2018 Apr — 256-264
Ileocolonic tuberculosis clinically, endoscopically, and radiologically mimicking Crohn's disease: disseminated infection after treatment with infliximab.
Journal of Crohn's & colitis 2014 Jun;8;560-2 — 2014 Jun — 560-2
Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases.
American journal of respiratory and critical care medicine 2011 Mar 01;183;675-8 — 2011 Mar 01 — 675-8
Hernández-Cruz B, Sifuentes-Osornio J, Ponce-de-León Rosales S, Ponce-de-León Garduño A, Díaz-Jouanen E
Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series.
Clinical and experimental rheumatology 1999 May-Jun;17;289-96 — 1999 May-Jun — 289-96
Tuberculosis in ulcerative colitis: bird in the bush.
Tropical gastroenterology : official journal of the Digestive Diseases Foundation 1994 Oct-Dec;15;219-21 — 1994 Oct-Dec — 219-21